AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that on February 3, 2025, AEON received a notice (the “Notice”) from the NYSE American LLC…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks